XML 20 R8.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 6 Months Ended 12 Months Ended
Dec. 31, 2020
Dec. 31, 2022
Dec. 31, 2021
Jun. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss attributable to Myriad Genetics, Inc. stockholders $ (53.1) $ (112.0) $ (27.2) $ (199.5)
Adjustments to reconcile net loss to net cash provided by operating activities:        
Depreciation and amortization 35.8 52.7 62.8 72.0
Non-cash interest expense 0.4 1.7 1.5 0.5
Non-cash lease expense 6.4 11.7 12.8 0.0
Tenant improvement allowance received 0.0 18.0 0.0 0.0
Stock-based compensation expense 14.9 38.1 36.3 25.2
Deferred income taxes 44.2 (30.8) (32.1) (55.8)
Unrecognized tax benefits 7.1 (1.1) (2.6) 1.7
Non-cash impact of foreign currency transactions (1.0) 0.0 0.0 0.0
Loss on inventory 0.0 0.0 6.5 0.0
Impairment of goodwill and long-lived assets 0.0 16.9 1.8 99.7
Gain on sale of businesses and assets 0.0 0.0 (162.0) (1.0)
Changes in assets and liabilities:        
Prepaid expenses and other current assets 3.1 1.6 (6.6) 2.8
Trade accounts receivable (21.4) (10.3) (8.8) 64.0
Inventory 2.2 (2.9) 1.6 1.6
Prepaid taxes (108.4) 0.7 89.9 25.1
Other assets (2.3) (0.9) (3.6) 0.0
Accounts payable (1.2) (3.5) 9.2 (10.7)
Accrued liabilities (0.2) (81.2) 65.7 4.4
Deferred revenue (0.2) (5.0) (26.6) 30.7
Net cash provided by (used in) operating activities (73.7) (106.3) 18.6 60.7
CASH FLOWS FROM INVESTING ACTIVITIES:        
Capital expenditures (7.9) (45.3) (18.0) (10.2)
Acquisitions, net of cash acquired 0.0 (57.2) 0.0 0.0
Proceeds from sale of business and assets 0.0 0.0 379.1 21.3
Purchases of marketable investment securities 0.0 (103.2) (147.8) (60.8)
Proceeds from maturities and sales of marketable investment securities 35.9 128.2 61.1 69.0
Net cash provided by (used in) investing activities 28.0 (77.5) 274.4 19.3
CASH FLOWS FROM FINANCING ACTIVITIES:        
Proceeds from common stock issued under stock-based compensation plans 1.8 6.3 91.8 13.3
Payment of tax withheld for common stock issued under stock-based compensation plans (3.8) (10.6) (11.5) (9.8)
Payment of contingent consideration recognized at acquisition (0.1) (3.0) (3.3) (3.9)
Fees associated with refinancing of revolving credit facility 0.0 (0.7) (1.2) (1.0)
Repayment of revolving credit facility 0.0 0.0 (226.4) (8.6)
Net cash used in financing activities (2.1) (8.0) (150.6) (10.0)
Effect of foreign exchange rates on cash, cash equivalents, and restricted cash 1.1 (0.6) (0.6) 0.5
Net increase (decrease) in cash, cash equivalents, and restricted cash (46.7) (192.4) 141.8 70.5
Cash, cash equivalents, and restricted cash at beginning of the period 163.7 258.8 117.0 93.2
Cash, cash equivalents, and restricted cash at end of the period $ 117.0 $ 66.4 $ 258.8 $ 163.7